A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination with the Modified Gemcitabine and nab-Paclitaxel Regimen Versus the Standard Gemcitabine and nab-Paclitaxel Regimen for the Treatment of Patients with Metastatic Pancreatic Ductal Adenocarcinoma Cancer (MAPKeeper 301)
Sponsor: Immuneering Corp.
Phase: 3
Disease: Metastatic pancreatic ductal adenocarcinoma
EU trial number: 2026-525617-31-00
Population: Adults with previously untreated metastatic pancreatic ductal adenocarcinoma, ECOG performance status 0–1, and at least one measurable metastatic lesion by RECIST 1.1.
Register Investigator Interest
Interested in offering this trial to suitable patients?